Purdue Pharma L.p.

Euro-celtique S.a.

Rhodes Pharmaceuticals L.p.

Richard S Sackler

Paul D Goldenheim

Ronald M Burch

Mark Chasin

Joseph Tigner

Derek Allan Prater

Robert F Kaiko

Malcolm Walden

Alexander Oksche

Timothy Holden

William Heath

Benjamin Oshlack

Thinnayam Naganathan Krishnamurthy

Andrew Darke

Mark Alfonso

Donna Donigi-Gale

Peter Lacouture

Curtis Wright

Ronald Brown Miller

Dileep Bhagwat

Anthony E Carpanzano

Robert F Reder

Alfred Halpern

Ihor Shevchuk

Lino Tavares

Benjamin Oshlaci

Dominic A Centrone

Thomas G Bunting

Rampurna Prasad Gullapalli

Bruce E Reidenberg

Mortimer D Sackler

Helmut E Rackur

Erwig O Pinter

Raymond R Sackler

Alfred Halpern, Deceased

James P Cassidy

Mark A Alfonso

Disclosed in certain embodiments is an oral dosage form comprising: a therapeutically effective amount of an opioid analgesic; an opioid antagonist; and an irritant in an effective amount to impart an irritating sensation to an abuser upon administration of the dosage form after tampering.

Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant agent

Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of an irritant to impart an irritating sensation to an abuser upon administration of said dosage form after tampering.

Pharmaceutical formulation containing irritant

Disclosed in certain embodiments is a solid oral dosage form comprising: (a) an inert tamper resistant core; and (b) a coating surrounding the core, the coating comprising an active agent.

Tamper resistant solid oral dosage forms

The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug substitution therapy in drug-dependent human subjects.

Buprenorphine-wafer for drug substitution therapy

Methods of preparing tamper resistant solid oral dosage forms

Disclosed in certain embodiments is an oral dosage form comprising:

Disclosed is a pharmaceutical composition, comprising two analgesic compounds and/or pharmaceutically acceptable salts thereof consisting of celecoxib and/or at least one pharmaceutically acceptable salt thereof and oxycodone and/or at least one pharmaceutically acceptable salt thereof, said two analgesic compounds in an amount sufficient to provide an analgesic effect in a human patient. Also disclosed is a method of effectively treating pain in humans or other mammals, comprising orally administering to the patient an oral dosage form comprising two analgesic compounds consisting of celecoxib and/or at least one pharmaceutically acceptable salt thereof and oxycodone and/or at least one pharmaceutically acceptable salt thereof, said two analgesic compounds in an amount sufficient to provide an analgesic effect in a human patient.

Analgesic combination of oxycodone and celecoxib

Pharmaceutical formulation containing an opioid agonist, opioid antagonist and irritant agent

Growing community of inventors

Greenwich, CT, United States of America

Richard S Sackler